These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18479495)

  • 1. HCV replication and statin pleotropism: an adjuvant treatment panacea?
    Torres DM; Harrison SA
    Am J Gastroenterol; 2008 Jun; 103(6):1390-2. PubMed ID: 18479495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
    Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
    Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of statins in the treatment of chronic hepatitis C virus infection.
    Abd-Eldaem AA; Azmy MK; Ahmad YK; Badr GA; Houssein MA; El-Dahshan T
    J Egypt Soc Parasitol; 2012 Dec; 42(3):535-40. PubMed ID: 23469629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are statins a viable option for the treatment of infections with the hepatitis C virus?
    Verpaalen B; Neyts J; Delang L
    Antiviral Res; 2014 May; 105():92-9. PubMed ID: 24613180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Harrison SA; Rossaro L; Hu KQ; Patel K; Tillmann H; Dhaliwal S; Torres DM; Koury K; Goteti VS; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS
    Hepatology; 2010 Sep; 52(3):864-74. PubMed ID: 20568303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
    Atsukawa M; Tsubota A; Kondo C; Itokawa N; Narahara Y; Nakatsuka K; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Kanazawa H; Sakamoto C
    J Gastroenterol Hepatol; 2013 Jan; 28(1):51-6. PubMed ID: 22989264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
    J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.
    Sheridan DA; Bridge SH; Crossey MM; Felmlee DJ; Fenwick FI; Thomas HC; Neely RD; Taylor-Robinson SD; Bassendine MF
    Liver Int; 2014 May; 34(5):737-47. PubMed ID: 24118830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells.
    Delang L; Scheers E; Grabner M; Verpaalen B; Helsen N; Vanstreels E; Daelemans D; Verfaillie C; Neyts J
    Biochem Pharmacol; 2015 Aug; 96(3):190-201. PubMed ID: 26070251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin helps interferon-based therapy in chronic hepatitis C: fact or fiction?
    Hsu CS; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):7-9. PubMed ID: 23278153
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
    Pandya P; Rzouq F; Oni O
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):555-65. PubMed ID: 25835493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and hepatitis C virus: friend or foe?
    Emanuele E
    Hepatology; 2010 Jan; 51(1):352. PubMed ID: 19603497
    [No Abstract]   [Full Text] [Related]  

  • 13. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
    Sezaki H; Suzuki F; Akuta N; Yatsuji H; Hosaka T; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2009; 52(1):43-8. PubMed ID: 19372703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients.
    Milazzo L; Meroni L; Galazzi M; Cesari M; Caramma I; Marchetti G; Galli M; Antinori S
    J Viral Hepat; 2009 Jul; 16(7):479-84. PubMed ID: 19215577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
    Selic Kurincic T; Lesnicar G; Poljak M; Meglic Volkar J; Rajter M; Prah J; Baklan Z; Kotar T; Maticic M
    Intervirology; 2014; 57(1):23-30. PubMed ID: 24080608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
    Ikeda M; Kato N
    J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of fluvastatin on HCV replication in HIV-1 coinfected subjects.
    Milazzo L; Antinori S
    J Viral Hepat; 2010 Mar; 17(3):228. PubMed ID: 19758276
    [No Abstract]   [Full Text] [Related]  

  • 18. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
    Bader T
    J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial.
    O'Leary JG; Chan JL; McMahon CM; Chung RT
    Hepatology; 2007 Apr; 45(4):895-8. PubMed ID: 17393518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.